Related Experiment Video

Updated: Mar 30, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

8.0K

Varying responses of PML-RARA with different genetic mutations to arsenic trioxide

Jiangying Liu1, Hong-Hu Zhu1, Hao Jiang1

  • 1Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Blood
|November 6, 2015
PubMed

Insights

Specific PML-RARA mutations in acute promyelocytic leukemia (APL) can cause resistance to arsenic trioxide. Understanding these genetic mutations helps predict treatment effectiveness and guide APL therapy strategies.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Arsenic trioxide and all-trans retinoic acid (ATRA) are key treatments for acute promyelocytic leukemia (APL).
  • Resistance to these therapies, often linked to mutations in the PML-RARA fusion gene, poses a significant clinical challenge.
  • The functional impact of specific acquired mutations within the PML moiety of PML-RARA on arsenic resistance is not fully understood.

Purpose of the Study:

  • To investigate the role of specific PML-RARA mutations in mediating resistance to arsenic trioxide in APL.
  • To analyze the functional differences between various point mutations in the PML part of PML-RARA.
  • To explore strategies for overcoming mutation-induced arsenic resistance in APL.

Main Methods:

  • In vitro functional analyses of five identified point mutations in the PML moiety of PML-RARA.
  • Retrospective analysis of APL patients to correlate genetic mutations with arsenic efficacy.
  • Assessment of arsenic trioxide concentration and combination therapy with ATRA to overcome resistance.

Main Results:

  • Mutations A216V, S214L, and A216T in PML-RARA attenuated arsenic's negative regulation, leading to oncoprotein retention and arsenic resistance.
  • Mutations L217F and S220G exhibited weaker effects on arsenic resistance.
  • Increased arsenic trioxide concentration or combination with ATRA effectively overcame mutation-triggered resistance in vitro.

Conclusions:

  • Specific acquired mutations in the PML moiety of PML-RARA differentially impact arsenic resistance in APL.
  • These findings reinforce the link between PML-RARA genetic mutations and arsenic efficacy, offering insights into resistance mechanisms.
  • Understanding these functional differences can aid in predicting APL prognosis and optimizing therapeutic strategies.

More Related Videos

In Vitro Scratch Assay to Demonstrate Effects of Arsenic on Skin Cell Migration09:24

In Vitro Scratch Assay to Demonstrate Effects of Arsenic on Skin Cell Migration

Published on: February 23, 2019

24.3K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

948

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
168
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
62